Rifamycin
| No ARVs during TB Rx | ARVs during TB Rx | ||||
| RIF n=34* | RBT n=1 | RIF n=28 | RBT n=54 | RIF + RBT n = 24 | |
| Black-African | 22 (65%) | 1 (100%) | 21 (75%) | 37 (69%) | 20 (83%) |
| Blood CD4 count (cells/mm3) | 350 (7–831) | 132 | 123 (13–500) | 124 (2–844) | 61 (11–233) |
| Completion of prescribed TB Rx | 30 (88%) | 1 (100%) | 27 (96%) | 52 (96%) | 23 (96%) |
| Grade III/IV AE | 14 (41%) | 0 | 20 (71%) | 17 (31%) | 16 (67%) |
| Recurrence of TB | 1 (3%) | 0 | 2 (7%) | 1 (2%) | 0 |
Entries are number (%) or median (range).
↵* 2 RIF pts had unknown ARV status